British Columbia Cancer Agency Branch

The University of British Columbia

Jinhe Pan

François Bénard

Kuo-shyan Lin

David Perrin

Zhengxing Zhang

Zhibo Liu

Hsiou-ting Kuo

Mathieu Lepage

Felix Mesak

Aron Roxin

This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is &#x2014;N(R)CHBF, a pyridinium group substituted with BFor methyl BF, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed. 

18/19F-labelled compounds which target the prostate specific membrane antigen

Bradykinin B1 receptor (B1R) targeting peptides and compounds are radiolabelled with radioisotopes that are suitable for imaging and/or radiotherapy. The radiolabelled peptides and compounds have utility in imaging tissues expressing or overexpressing B1R and/or treating diseases or conditions in which B1R is expressed or overexpressed, including cancer.

Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders

Growing community of inventors

Richmond, CA, United States of America

Jinhe Pan